Omalizumab: What have we learned after ten years of prescription?

Revue des maladies respiratoires
P PradèreC Taillé

Abstract

Omalizumab, an anti-immunoglobulin E monoclonal antibody, has now been used for ten years as an add-on therapy for severe adult atopic asthma, poorly controlled by high-doses inhaled steroids and long-acting beta-agonists. This innovative therapy has been the first biotherapy used on a large scale in severe asthma. It has shown clinical benefits, especially in the prevention of severe exacerbation, with a satisfactory safety profile. Despite its cost, it is an interesting alternative to continuous oral steroids, which cause more long-term side effects. After ten-years of prescription of omalizumab, we review here the mechanism of action, the benefits, the main side effects, the cost-effectiveness and also the alternative indications of this interesting molecule. We also consider the practicalities of using omalizumab, particularly the importance a rigorous assessment of its efficacy after 16weeks of treatment, and possible future therapeutic indications. Omalizumab has proven its efficacy in large randomized studies but also in real life practice in severe allergic asthma.

References

Jun 1, 1996·American Journal of Respiratory and Critical Care Medicine·M HumbertA B Kay
Sep 1, 2001·The European Respiratory Journal·M SolèrG Della Cioppa
Apr 15, 2004·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·S T HolgateUNKNOWN Omalizumab 011 International Study Group
Jun 3, 2004·American Journal of Respiratory and Critical Care Medicine·Ratko DjukanovićJohn V Fahy
Jun 6, 2006·The Journal of Allergy and Clinical Immunology·Oliver NogaJoachim Seybold
Nov 17, 2009·The Journal of Allergy and Clinical Immunology·Bob LanierCarlos Fernandez Vidaurre
Mar 23, 2010·The Journal of Allergy and Clinical Immunology·Hitendra S ChandMary F Lipscomb
Oct 12, 2010·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Stephanie KornRoland Buhl
Mar 18, 2011·The New England Journal of Medicine·William W BusseChristine A Sorkness
Apr 9, 2011·American Journal of Respiratory and Critical Care Medicine·Jonathan MouthuyCharles Pilette
Apr 27, 2011·Allergy·I Tillie-LeblondB Wallaert
Sep 22, 2011·Current Medical Research and Opinion·Zenon SiergiejkoRobert Maykut
Jan 13, 2012·Respiration; International Review of Thoracic Diseases·Makoto Hoshino, Junichi Ohtawa
Jun 12, 2012·Archives of Disease in Childhood·Malcolm BrodlieDavid A Spencer
Jan 1, 2010·BMJ Case Reports·Camille TailléMichel Aubier
Sep 27, 2012·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Sarah M BrayAndrej A Petrov
Oct 16, 2012·Current Allergy and Asthma Reports·Jay A Lieberman, Mirna Chehade
Dec 4, 2012·Journal of Asthma and Allergy·Jennifer CollinsDavid Rosenstreich
Jan 29, 2013·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Luis Pérez de LlanoUNKNOWN Spanish Registry
Mar 19, 2013·Chest·Lamiae Grimaldi-BensoudaUNKNOWN Pharmacoepidemiology of Asthma and Xolair (PAX) Study Group
Mar 23, 2013·The European Respiratory Journal·Antoine DeschildreJocelyne Just
Jun 5, 2013·International Archives of Allergy and Immunology·Yotaro TakakuMakoto Nagata
Jun 25, 2013·The Journal of Allergy and Clinical Immunology·Donald W Macglashan, Sarbjit S Saini
Oct 16, 2013·Journal of the American Academy of Dermatology·Jonathan Lacombe BarriosAnne Des Roches
Nov 2, 2013·The Journal of Allergy and Clinical Immunology·Lynda C SchneiderDale T Umetsu
Dec 7, 2013·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·Gert-Jan BraunstahlChien-Wei Chen
Dec 18, 2013·The European Respiratory Journal·Kian Fan ChungW Gerald Teague
Mar 1, 2014·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·Philippe BéginKari C Nadeau
Apr 1, 2014·The Journal of Allergy and Clinical Immunology·Aidan LongStanley J Szefler

❮ Previous
Next ❯

Citations

Feb 13, 2017·Revue des maladies respiratoires·J-M Perotin, C Barnig
Jan 15, 2019·Annales de dermatologie et de vénéréologie·A HamelinA Soria
Nov 16, 2018·Revue des maladies respiratoires·C TailléF Albers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Allergies & Environmental Factors

Environmental factors are strongly associated with the prevalence of allergies and are an increasing health concern worldwide. Discover the latest research on Allergies and Environmental Factors here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.